1342802-95-2

Upstream product

• 1226807-99-3 [(2-amino-5-chlorobenzyl)-tert-butoxycarbonylamino]acetic acid ethyl ester 
• 1226808-00-9 7-chloro-2-oxo-1,2,3,5-tetrahydrobenzo[1,4]diazepine-4-carboxylic acid tert-butyl ester 
• 73033-58-6 5-chloro-2-nitrobenzyl alcohol 
• 57750-81-9 4-chloro-2-(chloromethyl)-1-nitrobenzene 
• 1339126-38-3 (RS)-4-pyridin-2-yl-cyclohex-3-enecarboxylic acid ethyl ester 
• 1342802-04-3 trans-4-pyridin-2-yl-cyclohexanecarboxylic acid ethyl ester 
• 1342802-03-2 cis/trans-4-pyridin-2-yl-cyclohexanecarboxylic acid ethyl ester 
• 1226807-98-2 [tert-butoxycarbonyl-(5-chloro-2-nitrobenzyl)amino]acetic acid ethyl ester 
• 1226807-97-1 7-chloro-2-thioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepine-4-carboxylic acid tert-butyl ester 
• 1342802-59-8 trans-4-pyridin-2-yl-cyclohexanecarboxylic acid hydrazide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 50608-35-0 (5-chloro-2-nitrobenzylamino)acetic acid ethyl ester 
• 122948-57-6 ethyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate 

Downstream Products

• 1342802-99-6 trans-8-chloro-5-methyl-1-(4-pyridin-2-yl-cyclohexyl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenzo[e]azulene 

Relevant academic research and scientific papers

Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder

We recently reported the discovery of a potent, selective, and brain-penetrant V1a receptor antagonist, which was not suitable for full development. Nevertheless, this compound was found to improve surrogates of social behavior in adults with autism spect

HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula (I) wherein R1, R2 and R 3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.